{"id":"meningitec","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Irritability"},{"rate":"5-10","effect":"Drowsiness"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide capsular material from N. meningitidis serogroup C conjugated to a protein carrier (tetanus toxoid), which enhances immunogenicity and T-cell dependent immune responses. This conjugation allows the vaccine to induce both IgG antibodies and immunological memory, providing protection against meningococcal meningitis and septicemia caused by serogroup C strains.","oneSentence":"Meningitec is a conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:18.573Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of meningococcal meningitis and septicemia caused by Neisseria meningitidis serogroup C in infants, children, adolescents, and adults"}]},"trialDetails":[{"nctId":"NCT00127855","phase":"PHASE2","title":"Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":409},{"nctId":"NCT01506193","phase":"PHASE3","title":"Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-02-06","conditions":"Rubella, Varicella, Measles","enrollment":716},{"nctId":"NCT00134719","phase":"PHASE2","title":"Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04-11","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":1104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MenC vaccine","Meningococcal C conjugate vaccine (Wyeth)."],"phase":"marketed","status":"active","brandName":"Meningitec®","genericName":"Meningitec®","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Meningitec is a conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C. Used for Prevention of meningococcal meningitis and septicemia caused by Neisseria meningitidis serogroup C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}